# TMC114IFD3001 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir(Rtv) in HIV1 Infected Adults, Adolescents and Children Aged 3 Years or Above and Coming From Previous Company Sponsored Studies With DRV

> **NCT01281813** · PHASE3 · COMPLETED · sponsor: **Janssen Sciences Ireland UC** · enrollment: 145 (actual)

## Conditions studied

- HIV-1 Infections

## Interventions

- **DRUG:** Darunavir
- **DRUG:** Ritonavir

## Key facts

- **NCT ID:** NCT01281813
- **Lead sponsor:** Janssen Sciences Ireland UC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08-08
- **Primary completion:** 2021-07-29
- **Final completion:** 2021-07-29
- **Target enrollment:** 145 (ACTUAL)
- **Last updated:** 2022-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01281813

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01281813, "TMC114IFD3001 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir(Rtv) in HIV1 Infected Adults, Adolescents and Children Aged 3 Years or Above and Coming From Previous Company Sponsored Studies With DRV". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01281813. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*